McManus Kathleen A, Pinkerton Relana, Dillingham Rebecca
Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
SAGE Open Med. 2014;2. doi: 10.1177/2050312114532809.
To describe the impacts of Virginia AIDS Drug Assistance Program's elimination of diabetes and hyperlipidemia medication on disease outcomes in people living with HIV.
Data were collected on two groups of people living with HIV who were prescribed medications for diabetes and/or hyperlipidemia; one group received medications from AIDS Drug Assistance Program (ADAP) and the other group received medications from another source. Data were collected for 13 months before and after the policy change. Diabetes, hyperlipidemia, and HIV control were compared using standard laboratory measures.
During the pre-policy-change time period, non-ADAP patients had better diabetes control than ADAP patients, but with multivariate analysis, ADAP status was no longer a statistically significant predictor. Otherwise, no significant differences between groups were identified.
ADAP patients had worse diabetes control compared to the non-ADAP group before the policy change. It is possible that this is due to the AIDS Drug Assistance Program population's poor access to non-HIV primary care, including care for diabetes. It is reassuring that, even during a time of flux in AIDS Drug Assistance Program resources, the AIDS Drug Assistance Program patients' co-morbid and HIV outcomes were not negatively impacted.
描述弗吉尼亚艾滋病药物援助项目取消糖尿病和高脂血症药物对艾滋病毒感染者疾病转归的影响。
收集两组接受糖尿病和/或高脂血症药物治疗的艾滋病毒感染者的数据；一组从艾滋病药物援助项目（ADAP）获得药物，另一组从其他来源获得药物。在政策变更前后13个月收集数据。使用标准实验室指标比较糖尿病、高脂血症和艾滋病毒控制情况。
在政策变更前的时间段内，非ADAP患者的糖尿病控制情况优于ADAP患者，但经过多变量分析，ADAP状态不再是具有统计学意义的预测因素。除此之外，未发现两组之间存在显著差异。
在政策变更前，ADAP患者的糖尿病控制情况比非ADAP组更差。这可能是由于艾滋病药物援助项目人群难以获得非艾滋病毒初级保健服务，包括糖尿病护理。令人欣慰的是，即使在艾滋病药物援助项目资源变动期间，艾滋病药物援助项目患者的合并症和艾滋病毒转归也未受到负面影响。
